MinersJOBirkettDJCytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Pharmacol.1998;45:525–538.
2.
AithalGPDayCPKestevenPJLDalyAKAssociation of polymorphisms in the cytochrome P450 CYP 2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet.1999;353:717–719.
3.
EvansWERellingMVPharmacogenomics: Translating functional genomics into rational therapeutics. Science.1999;286:487–491.
4.
MeyerUAPharmacogenetics and adverse drugs reactions. The Lancet.2000;356:1667–1671.
5.
WolfCRSmithGSmithRLPharmacogenetics. Science, medicine and the future. Br Med J.2000;320:987–990.
6.
PhillipsKAVeenstraDLOrenELeeJKSadeeW.Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA.2001;286:2270–2279.
